EİS ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR SANAYİ VE TİCARET A.Ş.

1 JANUARY – 30 JUNE 2026 ACCOUNTING PERIOD

BOARD OF DIRECTORS' ACTIVITY REPORT

EİS ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR SANAYİ VE TİCARET A.Ş.

BOARD OF DIRECTORS' ACTIVITY REPORT

Trade Name	: EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş.
Trade Registry Number	: Istanbul Trade Registry Office - 44943
Contact Information	: Büyükdere Caddesi, Ali Kaya Sokak No: 5 Levent 34394, Istanbul
Telephone	: 0 (212) 350 80 00 - 371 70 00 Fax: 0 (212) 371 73 99
Website	: www.eis.com.tr , www.eczacibasi.com.tr
Reporting Period	: 01.01.2026 – 30.06.2026

EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş. ("Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar" or the "Company") was established on 24 October 1951. The Company, which has a holding structure with its current subsidiaries and affiliates, has no actual manufacturing operations. Within this structure, the companies in whose capital the Company holds a direct interest as of 30 June 2026, together with their shareholding ratios, are shown in the table below:

Trade Name	**Shareholding Ratio (%)**
Gensenta İlaç Sanayi ve Ticaret A.Ş.	99.97
EİP Eczacıbaşı İlaç Pazarlama A.Ş.	99.92
Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş.	99.49
Eczacıbaşı İlaç Ticaret A.Ş.	94.70
Eczacıbaşı Holding A.Ş.[1]	37.28
Ekom Eczacıbaşı Dış Ticaret A.Ş.	26.36
VitrA Karo Sanayi ve Ticaret A.Ş.	25.00
Eczacıbaşı Bilişim Sanayi ve Ticaret A.Ş.	11.21

Capital and Shareholding Structure[2]

	30 June 2026		**31 December 2025**	
Shareholder	**Share Ratio (%)**	**Share Amount (TL)**	**Share Ratio (%)**	**Share Amount (TL)**
Eczacıbaşı Holding A.Ş.[3]	47.33	324,345,460.43	50.62	346,845,461
Eczacıbaşı Yatırım Holding Ortaklığı A.Ş.	30.62	209,803,928.39	30.62	209,803,928
Other (Publicly held portion)	22.05	151,110,611.18	18.76	128,610,611
Total	**100.00**	**685,260,000**	**100.00**	**685,260,000**

According to the data published by the Central Registry Agency (CRA) dated 30 June 2026, the actual free-float ratio is 22.02% of the Company's capital (31 March 2026: 18.73%).

[1] Our Company holds a 37.28% interest in the capital of Eczacıbaşı Holding A.Ş., our main shareholder, and has no directing influence over or control of the operating and investment policies of Eczacıbaşı Holding A.Ş. In our financial statements, it is included under the line item of financial assets whose fair value differences are reflected in other comprehensive income.

[2] On 15 April 2026, the sale by Eczacıbaşı Holding of shares with a total nominal value of TL 22,500,000 relating to EİS shares to foreign institutional investors by the accelerated bookbuilding method was carried out as a wholesale trade transaction on Borsa İstanbul. With this transaction, Eczacıbaşı Holding's direct shareholding in the EİS capital decreased from 50.62% to 47.33%, and the free-float ratio increased from 18.76% to 22.05%.

[3] The 2025 Corporate Brochure of Eczacıbaşı Holding A.Ş. can be accessed at https://www.eczacibasi.com.tr/assets/2025_corporate-brochure.pdf.

EİS ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR SANAYİ VE TİCARET A.Ş.

BOARD OF DIRECTORS' ACTIVITY REPORT

The Company's issued capital of TL 685,260,000 is divided into 68,526,000,000 shares each with a nominal value of 1 (one) kuruş. All shares are bearer shares. There are no privileged shares and each share carries one voting right. The Company has not acquired its own shares.

EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş. is traded on Borsa İstanbul A.Ş. (BIST) under the ticker ECILC in the Star Market (Yıldız Pazar).

Amendments Made to the Articles of Association During the Period and Their Reasons

No amendments were made to the Articles of Association during the period.

Board of Directors

The Board of Directors consists of a total of six members, two of whom are independent members. Information regarding the members of the Board of Directors who served during the period is provided below:

Name Surname	Position	Start Date of Term	Independence Status
Ferit Bülent Eczacıbaşı	Chairman of the Board	30 April 2026	-
Rahmi Faruk Eczacıbaşı	Vice Chairman of the Board	30 April 2026	-
Emin Fadıllıoğlu	Member	30 April 2026	-
İpek Güleç	Member	30 April 2026	-
Erol Ulukutlu	Member	30 April 2026	Independent Member
İhsan Rifat Öktem	Member	30 April 2026	Independent Member

During the period 1 January – 30 June 2026, the members of the Board of Directors did not engage in any activity contrary to the non-competition obligation.

Committees Formed Within the Board of Directors

In accordance with the provisions set out in the Corporate Governance Communiqué of the Capital Markets Board, the Board of Directors has formed the Audit Committee, the Corporate Governance Committee and the Early Detection of Risk Committee. The duties and responsibilities of the Nomination Committee and the Remuneration Committee are carried out by the Corporate Governance Committee. The members of our Company's committees who served during the period and the committee structures are set out below.

Audit Committee

Name - Surname	Position
Erol Ulukutlu	Chairman
İhsan Rifat Öktem	Member

Corporate Governance Committee

Name - Surname	Position
Erol Ulukutlu	Chairman
İpek Güleç	Member
Tuğçe Fetvacı	Member

Early Detection of Risk Committee

Name - Surname	Position
İhsan Rifat Öktem	Chairman
İpek Güleç	Member

The Board of Directors' Assessment of the Effectiveness of the Committees

The committees formed by the Board of Directors fulfilled their duties and responsibilities on the matters specified in their own charters and working principles, and took care to convene as frequently as deemed necessary for the effectiveness of their work. All resources and support needed by the committees to perform their duties were provided by the Board of Directors.

Changes in Senior Management During the Period and the Names, Surnames and Professional Experience of Those Currently in Office

There were no changes in senior management during the period. The position of General Manager of the Company is held by Emin Fadıllıoğlu.

Personnel and Labor Movements, Collective Bargaining Agreement Practices, Rights and Benefits Provided to Personnel and Employees

As of 30 June 2026, the Company's total number of personnel is 6[4] (31 March 2026: 5), all of whom are subject to the Labor Law. Collective bargaining agreement practices do not exist. The wages and rights of employees are determined in accordance with the relevant legislation and the internal regulations of the Eczacıbaşı Group. Within this framework, in addition to benefits such as private health and life insurance, individual pension, clothing, relocation and meal allowances, and marriage, birth-death and child allowances provided to employees according to the nature of their duties, employees are also given the opportunity to participate in training and career management programs appropriate to their personal and professional development. Within the organizational structure of EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş., the Legal and Investor Relations units report to the General Management.

Financial Information

	30 June 2026	31 December 2025
Liquidity Ratios		
- Current Ratio (%)	1.47	2.01
- Liquidity Ratio (%)	1.01	1.56
Financial Structure Ratios		
- Total Liabilities / Total Assets	0.19	0.19
- Total Equity / Total Assets	0.81	0.81
- Total Equity / Total Liabilities	4.29	4.37
Profitability Ratios		
- Net Profit (Loss) for the Period / Total Equity	-0.03	0.03
- Net Profit (Loss) for the Period / Total Assets	-0.02	0.03
- Net Profit (Loss) for the Period / Revenue	-0.36	0.21

Distributed Dividend and Its Rate

The dividend distribution proposal to distribute a cash dividend of TL 1,200,000,000 for the 01.01.2025-31.12.2025 accounting period was approved at the 2025 Ordinary General Assembly Meeting, and the dividend distribution was completed as of 8 May 2026.

[4]The consolidated number of employees is provided in the financial report.

The Company's dividend distribution information for the last five years is shown in the table below:

Year	Dividend Distribution Start Date	Amount (TL)	Rate (%)	
			Gross	Net
2021	24.05.2022	200,095,920	29.20	26.28
2022	25.04.2023	280,956,600	41.00	36.90
2023	05.06.2024	808,606,800	118.00	106.20
2024	14.05.2025	1,200,000,000	175.12	148.85
2025	06.05.2026	1,200,000,000	175.12	148.85

The Company's Sources of Financing

In order to be used in financing the acquisition of Gensenta İlaç Sanayi ve Ticaret A.Ş., a bank loan of Euro equivalent to USD 85,000,000 was obtained on 1 November 2022, with a 1-year principal grace period and a total maturity of 5 years. In practice, its cash assets, which constitute a significant portion of its net financial assets, consist of Euro, US Dollar and Turkish Lira. No capital market instrument was issued during the period.

The Investment Policy Applied to Strengthen the Company's Performance

The Company's investment policy has been defined as engaging in growth-oriented investment activities in the health and real estate development sectors.

Information on the Internal Control System and Internal Audit Activities

Internal control is the system that ensures that processes and transactions are carried out within the framework of the relevant legislation and rules and in accordance with management strategy and policies, that errors, fraud and irregularities are detected and prevented, that the integrity and reliability of the accounting and recording system are maintained, and that information in the data system can be obtained accurately and in a timely manner. The internal control system has been designed to provide reasonable assurance regarding the achievement of objectives relating to the effectiveness and efficiency of operations, the reliability of reporting, and compliance with the relevant legislation.

Elements such as standard definitions, duties and responsibilities, authorizations, and policies and procedures that are part of business process flows constitute the Internal Control System. This system, which also includes risk management, information systems and processes, is subject to evaluation within the scope of Internal Audit activities, and its effectiveness is audited.

The Audit Committee is responsible for reviewing the accounting system, the public disclosure of financial information, and the financial and sustainability reports and submitting them for the approval of the board of directors, determining the independent audit firm, and overseeing the operation and effectiveness of the internal control system as well as the independent audit processes. During the period, the Committee monitored the accounting and internal control systems, independent audit and financial reporting processes, did not encounter any adverse findings, and concluded that procedures were duly followed.

In addition to the duties carried out by the Audit Committee, the statutory records are checked quarterly by a Certified Public Accountancy firm in terms of the Turkish Commercial Code, the Uniform Chart of Accounts and Tax Legislation. Furthermore, the compliance of the annual financial statements for the January-June interim period and the January-December accounting period with the Turkish Financial Reporting Standards is audited by the independent audit firm.

The Corporate Risk Management Policy adopted in order to effectively manage the risks that may be encountered in the process of achieving strategic goals, to reduce uncertainties and to evaluate opportunities covers all units and activities of the Company and is aligned with the Group Corporate Risk Management Policy.

Information on Donations Made During the Period

As of 30 June 2026, the solo amount of donations made to public-benefit associations and foundations, universities, health institutions and organizations, and to organizations pursuing public-service purposes for the promotion and support of social, scientific, artistic and other activities beneficial to the country, as well as to special provincial administrations with annexed budgets and similar institutions, is TL 5,706 based on the purchasing power of the TL as of 30.06.2026.

Developments During the 01.04.2026-30.06.2026 Period

Registration of the Resolutions of the 2025 Ordinary General Assembly

The Company's Ordinary General Assembly meeting for the 2025 Fiscal Year was held as of 30 April 2026. At the General Assembly, it was resolved to appoint DRT Bağımsız Denetim ve Serbest Muhasebeci Mali Müşavirlik A.Ş. as the Independent Audit Firm to audit the financial statements; to appoint RSM Turkey Uluslararası Bağımsız Denetim Anonim Şirketi to perform the Mandatory Assurance Engagement for Corporate Sustainability Reports to be prepared in accordance with the Turkish Sustainability Reporting Standards published by the Public Oversight, Accounting and Auditing Standards Authority; to carry out the dividend distribution in line with the dividend distribution proposal; and to set the dividend payment date as 6 May 2026. The said ordinary general assembly resolutions were registered by the Istanbul Trade Registry Directorate on 11 May 2026. The dividend distribution was completed as of 8 May 2026.

Participation in the Capital Increase of Our Associate Vitra Karo Sanayi ve Ticaret A.Ş.

As stated in our Company's Public Disclosure Platform (KAP) announcement dated 15.05.2026;
Within the framework of the resolution of the Vitra Karo board of directors dated 15 May 2026 regarding the determination of the general assembly agenda including the amendment of the articles of association to increase the current capital of TL 3,650,000,000 of our associate Vitra Karo Sanayi ve Ticaret A.Ş. (Vitra Karo), in which our Company holds a 25% interest, by TL 1,100,000,000 to TL 4,750,000,000, our Company's Board of Directors resolved:

- to participate in the capital increase, fully and in cash, by acquiring 275,000,000 shares each with a value of 1 Turkish Lira, corresponding to the TL 275,000,000 attributable to our shareholding out of the TL 1,100,000,000 capital increase,
- that at least ¼ of the TL 275,000,000 attributable to our shareholding out of the amount to be increased in cash be paid before the registration of the capital increase, and the remaining portion be paid in cash within 24 months at the latest from the registration of the capital increase.

The Board of Directors resolved accordingly.

The general assembly resolution dated 11.06.2026 was registered on 22.06.2026.

Revision of Policies

The changes made to the sustainability policies applied by our Company were approved by our Board of Directors as of 21 May 2026, and the revised policies have been made available on our Company's website.

Publication of the 2025 TSRS-Compliant Sustainability Report

The 2025 TSRS-Compliant Sustainability Report, which contains information about our Company's sustainability practices and performance and was prepared in accordance with the Turkish Sustainability Reporting Standards pursuant to the regulations of the Republic of Türkiye Public Oversight, Accounting and Auditing Standards Authority and subjected to a mandatory sustainability assurance engagement by

RSM Turkey Uluslararası Bağımsız Denetim Anonim Şirketi, is publicly disclosed on the KAP and on our Company's website.

Significant Events Occurring Between the End of the Accounting Period and the Date the Relevant Financial Statements Were Announced

Regarding Our Property in Ayazağa

With respect to the project to be carried out under the Revenue Sharing in Return for Land Share and Construction in Return for Flat Agreement signed with Artaş İnşaat Sanayi ve Ticaret A.Ş. on our Company's property located in the Ayazağa District of Istanbul, the preliminary project approval was forwarded by the Istanbul Metropolitan Municipality to the Sarıyer Municipality, and the EIA process concluded positively.

Evaluation of Activities for the 1 January – 30 June 2026 Period

Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar has a holding-type structure; within this structure it engages directly in real estate development activities, while its subsidiaries and associates operate in the sectors indicated below.

Sector / Market of Operation	Company Name
Health	
Reference and generic pharmaceuticals market	Gensenta İlaç Sanayi ve Ticaret A.Ş EİP Eczacıbaşı İlaç Pazarlama A.Ş. Eczacıbaşı İlaç Ticaret A.Ş.
Real Estate	
	Ayazağa[5]
	Kanyon[6]
Real estate development	Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş.
Other	
Ceramic tile market	VitrA Karo Sanayi ve Ticaret A.Ş.
Export services	Ekom Eczacıbaşı Dış Ticaret A.Ş.

[5] On our property in Ayazağa there is a Revenue Sharing in Return for Land Share and Construction in Return for Flat Agreement.
[6] The entirety of the Kanyon Office Block and half of the Kanyon Mall are owned by our Company.

ACTIVITIES IN THE HEALTHCARE SECTOR

Gensenta İlaç Sanayi ve Ticaret A.Ş.

Gensenta İlaç Sanayi ve Ticaret A.Ş. (Gensenta), which has been operating for over a century, is one of Türkiye's leading pharmaceutical manufacturers with its expert staff and modern facilities. Having joined the Eczacıbaşı Group in 2022, Gensenta continued its activities in the areas of pharmaceutical and finished-drug production and research and development in the second quarter of 2026.

In the second quarter of 2026, Gensenta continued production at its Other Pharmaceuticals Production Unit facility in Istanbul – Yenibosna.[7]

Specialized in sterile production, the Company has also been carrying out its activities with high-capacity aseptic production experience for over 50 years. Exporting to more than 12 countries, Gensenta holds 195 marketing authorizations for 88 brands valid in Türkiye and 87 marketing authorizations for 21 brands valid internationally. As Türkiye's most experienced organization in the production of parenteral drugs in liquid and lyophilized forms in its large-capacity injectable ampoule and vial preparation units, Gensenta offers the drugs it produces in accordance with the world-standard "Current Good Manufacturing Practices (cGMP)" and "Current Good Laboratory Practices (cGLP)" rules at its production facilities to the service of human health in many countries abroad as well as domestically.

At its Other Pharmaceuticals Production Unit facility, as a contract manufacturer (Contract Manufacturing Organization (CMO)), in addition to producing Gensenta-branded products, it carries out the contract manufacturing of products for which Eczacıbaşı İlaç Pazarlama and certain customers based abroad hold the marketing authorizations. At Gensenta's Yenibosna facility, in the oral production area, production is carried out in capsule, tablet and film-coated tablet forms; in the sterile production areas, production is carried out in both liquid and lyophilized forms; and filling and lyophilization operations are performed in vial form. While in sterile production approximately 39 thousand bottles (vials) can be filled per hour, in solid production the facility has a capacity to produce 750 million tablets per year in tablets and 160 million capsules in capsules. Efficiency studies for the said facility were carried out during 2024, and these studies also continue in 2026. With the High-Speed Isolator-Based Vial Filling Line (Vial 4) Investment, which has a budget of approximately 32 million Euro for liquid and lyophilization fillings, it is aimed to provide Gensenta, in addition to its existing vial filling capacity, a 60% increase in sterile liquid vial filling capacity and a 24% increase in lyophilized vial capacity. As of the report date, the Vial 4 project is progressing in line with the envisaged project plan, and the installation of the equipment at the facility and the commencement of testing are planned for the second half of 2026. One of the most important features of the line is that, through isolator technology, the entire production line is managed within a closed process, minimizing possible human error from outside. While the additional production line is regarded as an important strategic investment aimed at Gensenta's growth targets in domestic and foreign markets, it is aimed to enter new country markets. In addition, an Investment Incentive Certificate has been obtained from the Republic of Türkiye Ministry of Industry and Technology in connection with the investment, comprising support elements of "VAT Exemption, Customs Duty Exemption, Tax Reduction (80%, Investment Contribution Rate 40%), Interest or Dividend Support and Employer's Share of Social Security Premium Support (7 Years)". Since the said investment qualifies as a "priority investment", the Investment Incentive Certificate covers fixed investments with a total value of TL 1,346,015,999, valid between 15.10.2024 and 15.10.2027, within the scope of the regional support applied in the 5th region. In order to provide financing for the said investment, the application made within the scope of the YTAK (Investment-Committed Advance Loan) was concluded at the end of May 2025, and the TSP (Technology Level Score) Certificate was delivered to Gensenta. Within the scope of the YTAK, a total of TL 775 million in loans with a 10-year maturity is planned to be used. Within this framework, the first tranche of TL 546 million was disbursed in April 2026, and the second tranche of TL 229 million is expected to be disbursed in December 2026.

[7] At the production facility located in Şekerpınar, by the Board of Directors Resolution dated 03.02.2026, within the framework of changes occurring in the demand conditions for products manufactured at the raw-material production facility and of compliance with production-efficiency and cost-optimization targets, it was resolved to permanently halt all production activities at the raw-material production facility as of 31.03.2026 and to completely close the facility, and to terminate the employment contracts of the 44 personnel working at the facility.

As of the end of 2025, it was decided to halt operations on the Ampoule Production Line located at Gensenta's Yenibosna campus, within the scope of modernization, due to the requirement for high investment; the technology transfer of the products manufactured on this line was carried out, and it was planned to transfer their production to third-party manufacturers on a contract-manufacturing basis. Depending on the completion of the technology transfer process, the packaging activities are expected to continue until August 2026. The decision taken is not expected to have a significant impact on Gensenta's operations and financials. The necessary notifications have been made to the Republic of Türkiye Ministry of Health and other authorities in accordance with the relevant legislation.

With the Council of Ministers Decision on the Pricing of Medicinal Products for Human Use dated 12 March 2026, the Euro value used in pricing was set at 65% of the previous year's average CBRT rate. Within the scope of the decision, a two-stage increase was applied during the transition period; as of 13 March 2026, TL 26.8767 is taken as the basis with a 60% coefficient, and as of 1 April 2026, TL 29.1164 is taken as the basis with a 65% coefficient.

In addition to its production activities, Gensenta maintains its presence among the strong players of the sector as one of the first R&D centers certified by the Ministry of Science, Industry and Technology. Within the scope of R&D activities, formulation development processes are managed with a holistic approach from the first stage to the final product, with a particular focus on the development of value-added generic products. The recent increase in the number of projects assigned to R&D supports the company's goal of strengthening its innovative and value-creating product portfolio. Among Gensenta's future targets, increasing the share of R&D projects within the company's activities remains a strategic priority.

Prominent activities in the second quarter of 2026

- While the number of medicinal product marketing authorizations held in Türkiye is 195, this number in international markets is 87.
- On 12.02.2026, an Asset Purchase Agreement was signed for the transfer from Sanofi Sağlık Ürünleri Ltd. Şti. of 7 medicinal product marketing authorizations for human use belonging to 4 commercial trademarks (Azro, Diazomid, Furacin and Muscoril). The assets subject to the transfer cover only the domestic market, and an application was made to the Competition Authority to obtain permission for the transfer transaction. It is planned that, by carrying out the necessary technology transfer by the beginning of 2029, tablet and capsule forms will be produced from the acquired product marketing authorizations. As a result of the application made to the Competition Authority, the Competition Board resolved to grant permission for the transaction. [8] [9]
- Greenhouse gas measurements have been calculated, and science-based targets (SBTi - science based targets initiative) have been set for their reduction over the short and long term.
- In 2024, structural and non-structural seismic strengthening projects were completed in the buildings at the Yenibosna finished-drug facility. On the other hand, the arbitration proceedings conducted before the International Chamber of Commerce (ICC) by EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar against the seller, with a compensation claim of USD 3.26 million on the grounds that the seller failed to fulfill its obligations in the matter under the share transfer agreement signed during the acquisition of Gensenta, have been concluded. By the final decision contained in the arbitral tribunal's decision dated 16 June 2026, compensation of USD 2.34 million was awarded in favor of EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar, and it was further decided that a portion of the arbitration and litigation costs be borne by the defendants. All amounts awarded against the defendants have been collected.
- Technology has been transformed not merely into a supporting function, but into a fundamental lever that simplifies business processes, increases decision-making speed and enhances operational efficiency. Artificial intelligence has been positioned, beyond individual productivity, within a structure that creates corporate value in critical areas such as marketing, commercial management and quality.

[8] https://kap.org.tr/tr/Bildirim/1556220
[9] https://www.kap.org.tr/tr/Bildirim/1574194

- Digitalization initiatives such as DeviAI have made quality one of the cornerstones of operational excellence and sustainable growth.
- Within the scope of Gensenta's digital transformation roadmap, the digital transformation projects initiated to increase operational efficiency continue in line with the milestones set for 2026. Within the scope of these projects, progress is being made in line with the objectives of reducing the loss of time arising from manual processes, lowering costs and environmental impacts associated with energy consumption, and increasing business continuity and productivity through the proactive monitoring of critical performance indicators.
- Within the scope of the Microbiology Environmental Monitoring Sampling Process Tracking Project, the incentive, patent and award application processes are progressing according to plan; implementation, testing, training and validation studies are being carried out simultaneously.
- Within the scope of the Digital Maintenance Processes Project, maintenance operations have been moved to a digital platform, and a transition to a paperless working structure has been achieved in maintenance operations. Through this transformation, the traceability of processes has been increased, data entries have been standardized, and an important step has been taken to support operational efficiency; process improvements continue.
- In line with Gensenta's digital transformation targets, in order to strengthen a data-driven management approach and increase operational efficiency, AI-supported assistants integrated into the reporting infrastructure have been put into operation, and the corporate dashboard infrastructure actively used by management and operations teams has been expanded. Within this scope, while the interpretation of data, the proactive monitoring of critical performance indicators and the support of decision-making processes are ensured, reporting and data management solutions are continuously improved with an agile development approach in line with user feedback.
- Within the scope of the Gensenta Digital Transformation Support Program (DDDP) application process, a 5-year digital transformation project portfolio and investment plan have been created, and the technical and operational preparations within the scope of the incentive certificate application are ongoing. The digital transformation projects and roadmap determined as a result of the SIRI (Smart Industry Readiness Index) assessment carried out within the scope of the program application have been submitted to the Ministry of Industry and Technology. The relevant assessment and revision processes are ongoing, and work towards finalizing the application is being carried out according to plan. The program aims to accelerate digital transformation investments, increase operational efficiency and support the company's long-term transformation targets. Within this scope, the projects planned to be implemented aim to increase traceability in production, quality, logistics and maintenance processes, to expand the paperless operation approach, and to strengthen data-based decision-making capability.
- The projects carried out regarding capacity-utilization optimization and manufacturing excellence studies initiated in 2023 are progressing successfully in line with the determined plan. With the two new agile teams put into operation as of the second quarter of 2026, digitalization studies in quality and occupational health and safety processes have been accelerated; action management has been strengthened with a risk-based prioritization approach, and process performance has been more effectively monitored through the dashboard.
- Detailed disclosures regarding Gensenta's sustainability approach and the work carried out within this scope are presented in the EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar 2025 Annual Report.

The rights and benefits provided to personnel are in line with the human resources practices of the Eczacıbaşı Group. As of 30 June 2026, the Company has a total of 461 employees. (31 March 2026: 463)

EİP Eczacıbaşı İlaç Pazarlama A.Ş.

EİP Eczacıbaşı İlaç Pazarlama A.Ş. (EİP, Eczacıbaşı İlaç Pazarlama) was established in Istanbul in 1989. Through its collaborations with international and local firms in the pharmaceutical sector, it carries out the promotion, marketing, sale and distribution of reference/generic (equivalent) drugs and over-the-counter products that it imports, has contract-manufactured, or adds to its portfolio through sales and marketing agreements.

Eczacıbaşı İlaç Pazarlama carries out its activities through three main business areas, namely "Core

Therapies", "Specific Therapies" and "Consumer Health Products". In the Core Therapies area, there are products that have long been on the market and serve the primary-care level (Family Physician System). When determining the specific therapy areas, markets in which the company operates and which are expected to grow in the future were prioritized. Within this scope, four therapy areas have been determined, namely urology, dermatology, central nervous system, and oncology - hematology. In line with EİP's growth vision, while investments are being made and the portfolio is being developed in the specific therapies area, emphasis has been placed on initiatives aimed particularly at developing the generic portfolio in the oncology area. Diabetes and diabetes-related diseases are expected to create a significant economy in the coming period; accordingly, "diabetes" was added to the therapy areas in September 2025, and services began to be provided in this area as well. Eczacıbaşı İlaç Pazarlama also operates in the field of dietary supplements, which includes consumer health products that are freely priced and can be brought to market in a shorter time. Within this scope, Dynavit, its own brand in the food supplement area produced domestically, is the sponsor of the Eczacıbaşı Women's Volleyball Team, and its brand perception continues to be strengthened by providing more intensive media visibility. While efforts continue to add freely priced products in the dietary supplement class to its product range in addition to its reference and generic drug portfolio, the diversification of the Dynavit portfolio continues. The total number of dietary-supplement permits under the Dynavit brand is 85. In e-commerce, products under the Selfit brand, a special healthy-living brand, are sold through digital sales channels.

In addition to its own products, Eczacıbaşı İlaç Pazarlama represents the products of licensor companies. Within this scope, Eczacıbaşı İlaç Pazarlama, which has 12 business partners that are experts in their respective fields, includes in its product portfolio the products of Abdi İbrahim, Alfa Sigma, Almirall, Aspen, Galderma, Juvise, Novartis, Otsuka, P&G, Pharma Mar, Synthon and Tillotts.

One of the most important focuses of Eczacıbaşı İlaç Pazarlama is gross profitability, and efforts are being carried out to increase the market share or sales share of high-margin products and licensor products.

Eczacıbaşı İlaç Pazarlama has no R&D activities; however, within the scope of business development activities, studies are being carried out regarding molecules at the Phase III stage. In addition, product development studies with local firms in the fields of diabetes, dermatology and urology are ongoing. It is envisaged that the financial structure will be strengthened by concluding non-competing, high-priced new product agreements, by adding freely priced products with high market potential to the portfolio, and by rapidly evaluating co-marketing and marketing-authorization transfer options. Within the framework of new product agreements, collaboration efforts aimed at innovative products and at unmet patient needs in the oncology area continue.

As a result of the integration efforts between Gensenta and Eczacıbaşı İlaç Pazarlama, cooperation is being carried out in various areas. In 2023, Eczacıbaşı İlaç Pazarlama took over the domestic marketing and sales of various products owned by Gensenta. Within this scope, the transfer of the marketing authorizations owned by Gensenta to Eczacıbaşı İlaç Pazarlama is under way. Currently, while Eczacıbaşı İlaç Pazarlama holds 58 marketing authorizations for a total of 35 brands, and 111 authorizations for 5 brands in the dietary-supplement area, it also receives contract-manufacturing services from Gensenta.

As of the end of June 2026, Eczacıbaşı İlaç Pazarlama ranked 27th in the Türkiye pharmaceutical market with a TL market share of 1.34% based on its trailing 12-month sales.

The prices of reimbursable drugs are converted to TL using a fixed euro rate, again set by the Ministry of Health, by taking the lowest price of the drug in five predetermined source countries in the European Union. With the Council of Ministers Decision on the Pricing of Medicinal Products for Human Use dated 12 March 2026, the Euro value taken as the basis in pricing was set at 65% of the previous year's average CBRT rate, and a two-stage increase is applied during the transition period. Within this scope, as of 13 March 2026, TL 26.8767 is taken as the basis with a 60% coefficient, and as of 1 April 2026, TL 29.1164 is taken as the basis with a 65% coefficient.

The most important factor challenging companies operating in the pharmaceutical sector, and particularly those engaged in imports, is the difference between the current Euro rate and the Euro rate calculated in the manner described above and used in determining drug prices. The prices of all drugs sold by Eczacıbaşı İlaç Pazarlama — prescription/over-the-counter or reimbursed/non-reimbursed — other than freely priced dietary supplements, are determined according to the Ministry of Health's pricing decree.

In order to support the growth potential of the Dynavit brand, which has been growing rapidly in recent times, and to create both strategic and long-term financial value, a letter of intent was signed between Eczacıbaşı İlaç Pazarlama and BV Portföy Yönetimi on 09.03.2026. Within the scope of this letter of intent, the activities relating to the Dynavit brand are to be separated from EİP and a new company is to be established; a venture capital investment fund application has been made by BV Portföy to support the growth of this company, and the approval process is awaited.[10]

In March 2026, EİP was inspected by the Republic of Türkiye Ministry of Health within the scope of routine GMP inspections, and in the inspection report delivered on 09.04.2026 it was reported that the inspection was successfully completed and that no critical non-conformity was identified.

The main factors affecting the performance of Eczacıbaşı İlaç Pazarlama

- The reference price system applied by the Ministry of Health, the euro value whose calculation method is announced by the Council of Ministers Decision used in the TL conversion, and the drug budget practice managed by the SSI (SGK),
- The share of the drug budget within GDP remaining limited / not being increased over the years,
- The Ministry of Health marketing-authorization process,
- The speed at which authorized products enter the SSI's (SGK's) reimbursement lists,
- The SSI's (SGK's) mandatory public-institution discounts,

are considered to be the main factors.

Prominent activities in the second quarter of 2026

- Internal cultural digital transformation efforts continued without slowing down.
- Technology was transformed not merely into a supporting function, but into a fundamental lever that simplifies business processes, increases decision-making speed and enhances operational efficiency. Artificial intelligence was positioned, beyond individual productivity, within a structure that creates corporate value in critical areas such as marketing, commercial management and quality.
- The management and tracking of technology projects has been strengthened with the new Project Management Office structure, and these efforts continue.
- While talent management programs to increase talent depth are being implemented, efforts in this direction continue.
- With the digital marketing activities and innovative campaigns carried out under the Dynavit brand, its strong presence in the consumer health area continues, and brand awareness continues to be increased through social media interactions and digital campaigns.
- Efforts to move the customer experience journey to the digital environment continue.

Eczacıbaşı İlaç Pazarlama has no unionized employees. The rights and benefits provided to personnel are in line with the human resources practices of the Eczacıbaşı Group.

As of 30 June 2026, Eczacıbaşı İlaç Pazarlama has a total of 419 employees. (31 March 2026: 434) The Head Office, where Eczacıbaşı İlaç Pazarlama manages all of its personnel, is located in Levent (Istanbul). It operates throughout Türkiye, together with the other provinces where it has resident employees.

[10] https://www.kap.org.tr/tr/Bildirim/1569029

Eczacıbaşı İlaç Ticaret A.Ş.

The main field of activity of Eczacıbaşı İlaç Ticaret A.Ş. is the import and export and domestic wholesale trade of drugs, drug raw materials and preparations within the framework of the applicable import and export regimes. The Company has no active operations or personnel.

REAL ESTATE ACTIVITIES

Kanyon Office and Shopping Mall

Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar owns 50% of Kanyon, one of Istanbul's leading living, experience and shopping destinations, and the entirety of the 26-storey office block ("Kanyon Office").

Kanyon Office comprises 25 floors of 1.167 m^2 each, with a total leasable office area of 29.175 m^2. Kanyon Mall, on the other hand, features 147 stores, 16 kiosks, a 9-screen cinema, a premium fitness and sports club, restaurants and cafés, and a total parking capacity of 1.134 vehicles, with a leasable area of 41.102,5 m^2. Kanyon brings together carefully selected brands across fashion, gastronomy, culture-arts and lifestyle, offering its visitors a multi-layered and rich experience.

Kanyon is included among investment properties in the financial statements of Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar, and value-appreciation income and rental income are derived from the said properties.

In addition to its architecture, location and physical environment offering different experiences, Kanyon strengthens its differentiated position in the sector through its management, sustainability efforts, dynamic marketing projects, art-music-dance events, chatbot, artificial intelligence and digital technology use, and particularly its chef restaurants and brands.

As of the second quarter of 2026, the mall occupancy rate at Kanyon Mall is 98.59%, and the Kanyon Office occupancy rate is 94.3%. Kanyon's brand mix continues to be strategically developed in line with changing consumer expectations and lifestyle trends. Within this scope, short-term pop-up stores and stand rentals reflecting current trends and attracting interest are carried out to make room for new brands.

The main focus areas of marketing activities consist of event management, advertising, public relations, digital marketing, social media applications and customer relationship management activities in line with a 360-degree communication approach. The marketing calendar is planned throughout the year to increase the number of guests and store turnovers, to strengthen the Kanyon brand perception, and to offer visitors different experiences through innovative trends and experiences.

While new shopping malls and living spaces opened in different regions increase competition in the sector, Kanyon continues to differentiate itself in this competitive environment through its experience-oriented approach, strong brand mix and content strategies. In this direction, it is aimed to strengthen the loyal visitor base and to continuously improve the visitor experience.

Hosting the stores of many international brands, Kanyon aims to enhance the shopping experience of its guests by supporting local brands with growth potential that will set trends and by including different local producers in its mix. In line with this approach, Kanyon creates a multi-layered experience area for its guests with its selective and balanced brand mix. Kanyon has achieved a great success as the first commercial building in Türkiye to receive the "Outstanding"-level certificate as a result of the evaluations made in terms of design, building management and environmental performance in line with the "BREEAM" criteria applied to buildings in operation. In addition, it has achieved international success by outperforming other candidates in the "BREEAM Retail In-Use" category among multi-purpose buildings such as stores, offices and residences.

Kanyon not only integrates sustainability into its operational processes but also positions it at the center of its brand approach. With the goal of a sustainable world, it effectively manages its environmental impacts and aims to zero out its carbon emissions. In this direction, as of 2025, it holds the Renewable Energy Source Guarantee System (YEK-G) Certificate in cooperation with Enerjisa, and the carbon emissions arising from purchased electricity consumption are zero.

From 2016 until the end of the second quarter of 2026, a total of 97.4 tons of domestic waste was recycled, yielding 36 tons of compost in return. Making continuous improvements through efforts such as obtaining the ISO 14001 environmental management system and zero-waste certificates, the commissioning of a cogeneration system following a 100-panel solar energy system that heats water and reduces annual domestic-water energy consumption by up to 35%, the expansion of LED lighting, acoustic measurement and insulation, the installation of a carbon filter on the extractor exhaust system, and cooperation with the ITU Energy Institute, Kanyon makes room for a local producer every week and strengthens its image of sustainability and ethical environmental awareness through the brand it has created with the “Organikanyon” organic and natural products market held two days a week. With the aim of adding another to its certificates, Kanyon began, as of 2025, to fulfill the requirements of the Turkish Accreditation Agency (TÜRKAK)-approved ISO 50001 standard, which targets the continuous improvement of energy efficiency, energy use and energy performance in the activities under its control. In March 2026, the ISO 50001:2018 certificate was renewed. This certificate, together with surveillance audits, remains valid until April 2027. On 10 April 2026, the ISO 14001:2015 Environmental Management Systems certificate was successfully renewed following the URS audit and remains valid until 1 September 2029.

Kanyon is the first e-charge shopping mall in Türkiye, with a 24-vehicle charging station in its parking area. With the increase in the demand for and use of electric vehicles year by year, from 2023 until the end of the second quarter of 2026, a total of 37.811 vehicles were charged and a reduction of 1.781 tons of CO^2 was achieved. These investments support Kanyon's vision of adapting to the mobility and sustainable-living needs of the future.

The scenarios and events implemented at Kanyon also contribute to raising awareness in the field of sustainability. With the support of Türkiye İş Bankası and the project concept of Marketing Toys, the İş'te Minik Kaşifler Sokağı (Little Explorers' Street) was created. With this special experience area designed with the “Play, discover, protect” approach, it is aimed to instill environmental awareness and sustainable-living habits in children. At different play stations such as a digital play area, a seagrass maze, climbing hills and a wave slide, children are enabled to develop their physical skills while discovering marine life, biological diversity and the delicate balance of the ecosystem.

Prominent activities in the second quarter of 2026

In the second quarter of 2026, Kanyon continued to strengthen the brand experience implemented within the scope of its 20th anniversary through events, collaborations and digital communication projects.

In April, Kanyon hosted thousands of sports enthusiasts as the official race-kit distribution point for the Türkiye İş Bankası Istanbul Half Marathon and the İstanbul'u Koşuyorum organizations. On 23 April, National Sovereignty and Children's Day, the İş'te Minik Kaşifler Sokağı, implemented in cooperation with Türkiye İş Bankası, was brought together with visitors. With play mechanisms and experience areas designed with inspiration from important elements of the underwater ecosystem such as seagrass meadows and pinnae, it was aimed for children to discover marine ecology, to gain awareness of biological diversity, and to experience the awareness of sustainable living in an enjoyable way. In addition, with the Imagineer Studio Fest festival, children and their families were brought together with stage shows and fun activities, while the sustainability-themed workshops organized in cooperation with Puduhepa ve Kız Kardeşleri also offered content supporting environmental awareness.

In May, within the scope of 19 May Commemoration of Atatürk, Youth and Sports Day, a youth festival featuring themes such as sports, dance, music and well-being was held with the support of Zuhal Müzik, Mac/One, Sneaks Up, Saf and many other Kanyon brands.

In June, within the scope of World Environment Day, creative workshops themed on recycling, reuse and living in harmony with nature, sustainable design practices and book-reading events were held. In addition, with the Acısıyla Tatlısıyla 20 Yıl Kanyon'da (20 Years at Kanyon, with Its Bitter and Sweet) event organized specially for Kanyon's 20th anniversary, gastronomy, entertainment and experience were brought together; guests were offered an enjoyable festival experience throughout the day with bitter-sweet tasting experiences, award-winning competitions, live music, DJ performances and stage performances. June concluded with the Gripin concert and DJ performance held in cooperation with Troy x Marshall.

During the same period, the visibility of Kanyon brands and visitor engagement were supported with special digital communication projects and social media campaigns for Mother's Day and Report-Card Day.

Finally, within the scope of digital transformation efforts, the Kanyon Mobile Application, renewed for the 20th anniversary, was brought together with users; with its newly developed interface, its infrastructure improving the user experience, and its privileged campaign concepts, it has become an important touchpoint that strengthens visitors' Kanyon experience in the digital environment as well.

In the third quarter of 2026, the enrichment of the guest experience will continue with the events to be held within the scope of special-day celebrations and Kanyon's 20th anniversary celebrations.

As of 30 June 2026, the total rental income derived by Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar from the Kanyon Office and Shopping Mall is TL 468,922 thousand.

Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş.

Operating in the real estate sector in the field of real estate development and project management, Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım does not own any real estate of its own, and the Company's operating revenues consist of the revenues generated from the projects whose management it undertakes through service agreements.

As of 30 June 2026, the number of employees of Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım is 13 (31 March 2026: 14), and there are no collective bargaining agreement practices. The rights and benefits provided to personnel are in line with the human resources practices of the Eczacıbaşı Group.

Ayazağa Cendere Valley Urban Transformation Area

On our properties located within the Ayazağa, Cendere Valley Urban Transformation Area, a Revenue Sharing in Return for Land Share and Construction in Return for Flat Agreement was signed in July 2023 with Artaş İnşaat Sanayi ve Ticaret A.Ş. (the "Contractor") for the purpose of developing a revenue-sharing-based real estate project, subject to the completion of all legal processes and conditions envisaged in the agreement for the realization of the project, including the application of Article 18 of the Zoning Law, the zoning plan, and the construction/building permit processes required under the applicable zoning plan. Under the agreement, the contractor is responsible for carrying out all project processes and obtaining the necessary permits and licenses; it will develop the independent units to be sold to third parties by assuming all construction, marketing, sales and other related expenses. The revenue-sharing ratio in the project has been set at 47% for our Company and 53% for the Contractor.
Within the scope of the Zoning Application under Article 18 of Zoning Law No. 3194, following the finalization of the parcelization plan prepared as a result of the land and site regulation work carried out by the Sarıyer Municipality in the said region, it was approved by the Cadastre Directorate and registered by the Land Registry Directorate on 17.03.2025, and the land title deeds were issued. The title deed resulting from the legal deductions is approximately 41.5 thousand square meters in total.
Regarding the project, the preliminary project approval was forwarded by the Istanbul Metropolitan Municipality to the Sarıyer Municipality, and the EIA process concluded positively.

OTHER ASSOCIATES

VitrA Karo Sanayi ve Ticaret A.Ş.

VitrA Karo Sanayi Ticaret A.Ş. (VitrA Karo), which has ranked first for eight consecutive years in exports from Türkiye to the EU with tile products suitable for use in many different areas such as bathrooms, pools, gardens and façades, began its operations in 1991. Producing ceramic tiles at its factory in Russia since 2011 as well, VitrA Karo's total annual domestic and international production capacity is 31 million square meters.

VitrA Karo's production activities are carried out in Türkiye at Bozüyük (Bilecik) and at the production facility in Russia belonging to its subsidiary Vitra Tiles Llc.

Operating in 55 countries, primarily Türkiye and Germany, with the VitrA, Villeroy & Boch and engers brands, VitrA Karo realizes, on an annual average, 80% of its sales to foreign markets.

VitrA Karo's Bozüyük Production Facility became the first production facility from the ceramic tile sector to be included in the Industry 4.0 and digital Global Lighthouse Network by the World Economic Forum (WEF).
Reducing its carbon footprint in production by approximately 60% and ranking among Europe's best tile manufacturers, VitrA Karo meets more than 60% of the electricity it uses in Türkiye from its own renewable energy plant, and as Türkiye's first and only manufacturer of porcelain tiles with 100% recycled content, it leads its sector with an innovative production approach that contributes to the circular economy.

VitrA Karo's tiles, which hold the "TSE Double Star" Certificate, also hold the first eco-label granted by the European Union to a ceramic brand from Türkiye.

In the second quarter of 2026, tile sales in the Türkiye market, which accounts for 32% of VitrA Karo's consolidated sales revenue, were realized approximately 21% above the same period of the previous year on a Turkish Lira basis.

According to the May 2026 construction cost index and May housing sales statistics published by the Turkish Statistical Institute (TÜİK):

- The construction cost index increased by 1.87% in May 2026 compared with the previous month and by 29.84% compared with the same month of the previous year. Compared with the previous month, the materials index increased by 1.77% and the labor index by 2.04%. In addition, compared with the same month of the previous year, the materials index increased by 28.62% and the labor index by 32.00%.

- The building construction cost index increased by 1.96% compared with the previous month and by 28.56% compared with the same month of the previous year. Compared with the previous month, the materials index increased by 2.08% and the labor index by 1.75%. In addition, compared with the same month of the previous year, the materials index increased by 26.93% and the labor index by 31.34%. The construction cost index for non-building structures increased by 1.60% compared with the previous month and by 34.06% compared with the same month of the previous year. Compared with the previous month, the materials index increased by 0.85% and the labor index by 3.08%. In addition, compared with the same month of the previous year, the materials index increased by 33.91% and the labor index by 34.34%.

- Across Türkiye, the number of first-hand housing sales increased by 23.1% in June compared with the same month of the previous year, reaching 43,406. Second-hand housing sales, on the other hand, increased by 12.5% in June compared with the same month of the previous year, reaching 86,573. Within total housing sales, the share of first-hand housing sales was 33.4% and the share of second-hand housing sales was 66.6%. Across Türkiye, mortgaged housing sales increased by 72.1% in June compared with the same month of the previous year, reaching 25,993. Other housing sales, on the other hand, increased by 7.1% in June compared with the same month of the previous year, reaching 103,986. Within total housing sales, the share of mortgaged sales was 20.0% and the share of other sales was 80.0%. In the calendar-adjusted series, compared with the same month of the previous year, first-hand housing sales decreased by 1.5% and second-hand housing sales by 8.6%. In the seasonally and calendar-adjusted series, compared with the previous month, first-hand housing sales increased by 2.3% and second-hand housing sales by 0.9%. Housing sales to foreigners increased by 20.1% in June compared with the same month of the previous year, reaching 2,015. In June, the share of housing sales to foreigners within total housing sales was 1.6%. In the January-June period, housing sales to foreigners decreased by 9.2% compared with the same period of the previous year, reaching 9,083. In June, the most housing sales by country nationality were made, in order, to citizens of the Russian Federation with 381, Ukraine with 170 and Iran with 170.

VitrA Karo's total production quantity at its facilities in Türkiye and Russia increased by 0.5 million m^2 compared with June of the previous year, reaching a level of 13.8 million m^2. Approximately 87% of total production is carried out at the Türkiye facilities.

VitrA Karo has collective bargaining agreement practices in Türkiye, and blue-collar employees hold the rights and benefits covered by this agreement. White-collar employees, on the other hand, benefit from the rights and benefits determined by the Eczacıbaşı Group. At the Russia factory, there is no union affiliation and, accordingly, no collective labor agreement.

Ekom Eczacıbaşı Dış Ticaret A.Ş.

Established in 1981 as the foreign trade capital company of the Eczacıbaşı Group, Ekom Eczacıbaşı Dış Ticaret A.Ş. (Ekom) provides operations, customs, financing and risk management services to the companies of the Eczacıbaşı Group within the framework of export intermediation.

Ekom's performance is partly affected by changes in macroeconomic indicators. In particular, since fluctuations in exchange rate policy affect the commission income received on sales, they are directly reflected in the Company's financial results.

Since the marketing and sales organization is carried out by the manufacturing firms served, developments in this regard occur outside Ekom's initiative. Because it is an intermediary firm, it cannot intervene in the production, marketing and sales policies of the products whose export it facilitates. Measurements regarding the cost and quality of the intermediation services provided are made regularly.

Ekom, which has no R&D activities, makes limited investments to the extent required by its operational services. The Group companies it serves benefit from the advantages provided by its status as a Foreign Trade Capital Company. Since the equity of Ekom, an intermediary firm that assumes minimum-level risk in this intermediation process, is of sufficient size for this activity, Ekom does not use external financing for its own needs. As of 30 June 2026, the number of employees of Ekom is 20 (31 March 2026: 20).

DECLARATION OF RESPONSIBILITY PREPARED PURSUANT TO ARTICLE 9 OF CAPITAL MARKET BOARD'S COMMUNIQUÉ NUMBERED II-14.1 ON PRINCIPLES GOVERNING FINANCIAL REPORTING IN THE CAPITAL MARKET

RESOLUTION OF THE BOARD OF DIRECTORS REGARDING THE APPROVAL OF THE FINANCIAL STATEMENTS AND ACTIVITY REPORTS
RESOLUTION DATE : 06.08.2026
RESOLUTION NUMBER : 2026/23

Within the scope of the Capital Markets Board ("CMB") Communiqué No. II-14.1 on the Principles of Financial Reporting in the Capital Market (the "Communiqué") and in accordance with the Turkish Accounting Standards/Turkish Financial Reporting Standards ("TAS/TFRS") published by the Public Oversight, Accounting and Auditing Standards Authority ("KGK"), and prepared in conformity with the formats determined by the KGK and the CMB, the Financial Reports prepared by our Company for the period 1 January 2026 – 30 June 2026 — comprising the consolidated Statement of Financial Position, Statement of Profit or Loss, Statement of Other Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows compared with the previous period, together with the related Notes and the Activity Report (the "Financial Reports") — in line with the CMB regulations, we declare that:

a) they have been reviewed by us,

b) within the framework of the information we have in our area of duty and responsibility at our Company, they do not contain any misstatement on material matters or any deficiency that could render them misleading as of the date of disclosure,

c) within the framework of the information we have in our area of duty and responsibility at our Company, the financial statements prepared in accordance with the Communiqué fairly reflect, together with those within the scope of consolidation, the truth regarding the assets, liabilities, financial position and profit and loss of the enterprise, and the activity report fairly reflects the development and performance of the business and, together with those within the scope of consolidation, the financial position of the enterprise, along with the material risks and uncertainties faced,

we hereby submit for your information and declare that we are responsible for the disclosure made.

Respectfully,

Erol Ulukutlu - Chairman of the Audit Committee

İhsan Rifat Öktem - Member of the Audit Committee

Emin Fadıllıoğlu - General Manager